register

News & Trends - Pharmaceuticals

AstraZeneca secures PBS listing of its SGLT2 inhibitor for heart failure

Health Industry Hub | March 4, 2024 |

Pharma News: AstraZeneca’s SGLT2 inhibitor has been listed on the Pharmaceutical Benefit Scheme (PBS) starting March 1st. Forxiga (dapagliflozin) is indicated for the treatment of chronic heart failure with preserved ejection fraction, where the left ventricular ejection fraction (LVEF) exceeds 40%.

This development follows on the heels of the November 2023 inclusion of Boehringer Ingelheim-Eli Lilly’s SGLT2 inhibitor, Jardiance (empagliflozin), for the same category of heart failure. A meta-analysis comparing Forxiga and Jardiance at 10 mg revealed a significant improvement in preventing heart failure-related hospitalisations, with the efficacy of both treatments found to be “comparable”.

Adelaide-based cardiologist, Dr Alicia Chan, underscoresd the significance of this addition, stating “The listing of Forxiga for heart failure with preserved ejection fraction provides access to another option in the treatment of a serious chronic condition. My aim as a cardiologist is to work closely with my patients living with heart failure to manage their condition, which can help them stay out of the hospital and reduce the risk of cardiovascular death.”

Tanya Hall, CEO and Founder of hearts4heart, emphasised the importance of effective management. “Early diagnosis and proper treatment are key to enable people with heart failure to live a full and active life. As an organisation supporting people living with heart failure, we see the importance of new treatment options listed on the PBS and welcome this announcement from the Australian Government.”

Federal Minister for Health, Mark Butler MP, commented “Around 98,000 Australians living with chronic heart failure will now have another treatment choice thanks to the Albanese Government. About 180 Australians are hospitalised every single day with symptomatic chronic heart failure and they are often repeated hospitalisations.”

Ben McDonald, Country President of AstraZeneca Australia and New Zealand, expressed pride in the PBS listing, asserting “Thousands of Australians may now benefit from reimbursed access to Forxiga. AstraZeneca is proud of this PBS listing and will continue to invest in cardiovascular disease research and innovation in Australia.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.